Jiangsu Key Laboratory of Carcinogenesis and Intervention, China Pharmaceutical University, Nanjing, People's Republic of China.
Anticancer Drugs. 2011 Oct;22(9):886-95. doi: 10.1097/CAD.0b013e3283483d65.
FV-429 is a newly synthesized flavonoid with a bis(2-hydroxyethyl) amino propoxy substitution. In this study, we investigate the anticancer effect of FV-429 both in vivo and in vitro. These data have shown that FV-429 could significantly inhibit tumor growth in mice inoculated with Heps hepatoma cells without evident toxicity. After the treatment of FV-429 (40 mg/kg), the inhibitory rate of tumor weight was 52.12%. Then, we performed diamidinophenylindole staining and annexin V/propidium iodide double-staining assay to investigate the apoptosis induced by FV-429 in HepG2 cells. Further research revealed that FV-429 induced apoptosis through the mitochondrial apoptotic pathway, as indicated by a change in Bax/Bcl-2 ratios, collapse of mitochondrial membrane potential, the transposition of apoptotic-inducing factor and cytochrome c, caspase-3 and caspase-9 activation, and degradation of poly (ADP-ribose) polymerase. The accumulation of reactive oxygen species induced by FV-429 in HepG2 cells was also observed. Moreover, the mitogen-activated protein kinases, the downstream effect of reactive oxygen species accumulation including c-Jun N-terminal kinase and p38 mitogen-activated protein kinases, could be activated by FV-429. Taken together, our results provided a mechanistic framework for further exploration of FV-429 as a novel chemotherapy for human tumors.
FV-429 是一种新合成的黄酮类化合物,具有双(2-羟乙基)氨基丙氧基取代基。在本研究中,我们研究了 FV-429 在体内和体外的抗癌作用。这些数据表明,FV-429 可显著抑制接种 Heps 肝癌细胞的小鼠肿瘤生长,且无明显毒性。FV-429(40mg/kg)治疗后,肿瘤重量的抑制率为 52.12%。然后,我们通过吖啶橙染色和膜联蛋白 V/碘化丙啶双染实验来研究 FV-429 诱导 HepG2 细胞凋亡的情况。进一步的研究表明,FV-429 通过线粒体凋亡途径诱导细胞凋亡,这表现为 Bax/Bcl-2 比值的变化、线粒体膜电位的崩溃、凋亡诱导因子和细胞色素 c 的易位、caspase-3 和 caspase-9 的激活以及聚(ADP-核糖)聚合酶的降解。还观察到 FV-429 在 HepG2 细胞中诱导活性氧物质的积累。此外,FV-429 还可以激活丝裂原活化蛋白激酶,这是活性氧物质积累的下游效应,包括 c-Jun N 端激酶和 p38 丝裂原活化蛋白激酶。总之,我们的结果为进一步探索 FV-429 作为人类肿瘤的新型化疗药物提供了机制框架。